Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (33752)	3/10/2009 1:27:51 PM
From: voodooist	Read Replies (1) \| Respond to of 78659

Various possible suitors have been posited for BMY over the years, most notably SNY. A friend who studies the industry suggested that, now that BMY has divested itself of non-related parts (baby formula and cosmetics) he could envision a "new paradigm" with a major biotech such as AMGN acquiring them. FWIW. Full disclosure: very long BMY (it functions as a money market fund for me).

To: Paul Senior who wrote (33752)	3/10/2009 11:27:39 PM
From: Jurgis Bekepuris	Read Replies (1) \| Respond to of 78659

I thought about selling WYE and buying JNJ, but decided to wait for $33 and almost 1 share of PFE. There is still a good spread and I am comfortable enough with both WYE and PFE to continue holding. I will reassess situation once I receive the money. Today's the day for you to short BRK, whaddya think? ;)

To: Paul Senior who wrote (33752)	3/11/2010 11:23:05 AM
From: Paul Senior	Read Replies (2) \| Respond to of 78659

I'll trim my outsize ABT position now. Management has done a very good job integrating acquisitions, and maybe expensive purchase of FACT will be a winner as well. (Market participants seem to believe that: ABT stock hasn't fallen with the purchase announcement.) I show I've made 23 purchases of ABT beginning 3/10/09 through 8/12/09. It's become one of my largest positions. With ABT's acquisition now and with ABT's sales the drug Humira apparently slowing (18% of last year's revenue), I believe I'll adjust my risk/reward balance by reducing my position. Yahoo shows ABT with a current p/e of 15. That seems a tad high to me in today's market, but very good compared to prior years' higher numbers. Forward p/e is shown under 12, and by that, the stock would seem if not a buy, more of a buy than a sell. For me though, perhaps not worth keeping an outsize position on.